https://deriva.ai/assets/GeneDiseaseValidity-BfmKopQW.js

1import{a as e}from"./vendor-BmCPNSS_.js";import{E as a}from"./EducationalArticleTemplate-B9eaVcME.js";import"./index-DlQQAlQN.js";import"./supabase-IruhloFv.js";import"./Footer-CpevPqJt.js";import"./StickyMiniNav-DVY1iYfl.js";import"./ScientistCaseCTA-CosvbVNR.js";import"./NextReadSection-XLlJH2Jx.js";import"./FloralCTABanner-BLmscFDq.js";import"./midcta-bg-Ds5cY4OS.js";const t=1,n="8acd646d-37df-4da7-8f82-3a267d28e401",s="73e7875a-413f-4363-b969-9c18ef21c3d3",r="/__l5e/assets-v1/8acd646d-37df-4da7-8f82-3a267d28e401/beyond-the-variant.webp",o="a/v1/73e7875a-413f-4363-b969-9c18ef21c3d3/8acd646d-37df-4da7-8f82-3a267d28e401/beyond-the-variant.webp",d="beyond-the-variant.webp",l=106682,c="image/webp",h="2026-07-16T16:19:44Z",p={version:t,asset_id:n,project_id:s,url:r,r2_key:o,original_filename:d,size:l,content_type:c,created_at:h},g=[{name:"Definitive",text:"The role of the gene in the disease has been repeatedly demonstrated in both research and clinical diagnostic settings, and upheld over time (generally at least three years). No valid evidence has emerged that contradicts the association."},{name:"Strong",text:"The role of the gene in disease has been independently demonstrated in at least two separate studies with strong supporting evidence, such as multiple unrelated probands with pathogenic variants and compelling gene-level experimental data."},{name:"Moderate",text:"Disease supported by convincing genetic evidence, specifically probands harboring variants with sufficient evidence for causality, with or without experimental data, and no contradictory evidence."},{name:"Limited",text:"Limited evidence to support a causal role, such as a few probands with variants of unknown significance and limited experimental data."},{name:"No Known Disease Relationship",text:"No evidence has been reported in the medical literature or other sources to support a causal role for this gene in this disease."},{name:"Disputed",text:"Conflicting evidence has arisen since the initial report, significantly challenging the claim that the gene causes the disease."},{name:"Refuted",text:"Evidence significantly contradicts the claim that variation in this gene causes the disease, or the original clinical findings have been proven incorrect (e.g., due to a genotyping error or subsequent identification of the true causal gene)."}],u=[{type:"prose",id:"intro",eyebrow:"Introduction",heading:"The paradigm shift: from bigger panels to better genes",paragraphs:["In the early days of Next-Generation Sequencing (NGS), the clinical genomics philosophy was simple: sequence as many genes as possible. Large, extensive multi-gene panels were the standard, driven by the belief that casting a wider net would automatically yield higher diagnostic rates.","Today, clinical laboratories are facing the unintended consequences of that approach. By analyzing variants in genes with poor or unproven ties to specific phenotypes, labs have flooded their pipelines with unreportable data and driven their Variant of Uncertain Significance (VUS) rates through the roof.","To combat this, the clinical community is undergoing a massive paradigm shift. Before we ask if a variant is pathogenic, we must first ask: is the gene definitively linked to the disease?"]},{type:"prose",id:"framework",eyebrow:"The framework",heading:"The rise of the Gene-Disease Validity framework",paragraphs:["Gene-disease validity evaluates the strength of evidence supporting or refuting the claim that variation in a particular gene causes a particular disease. To standardize this, the Clinical Genome Resource (ClinGen) developed a semi-quantitative framework that scores genetic associations and categorizes them into distinct tiers of evidence (Strande et al., 2017).","Here are the exact classifications labs must now navigate:",e.jsx("ul",{className:"mt-2 space-y-4 list-none pl-0",children:g.map(i=>e.jsxs("li",{className:"border-l-2 border-violet-200 pl-4",children:[e.jsx("div",{className:"font-semibold text-slate-900",children:i.name}),e.jsx("div",{className:"text-slate-600 mt-1",children:i.text})]},i.name))},"tiers")]},{type:"prose",id:"data",eyebrow:"The data",heading:"The data behind the trend",paragraphs:["Over the past decade, formal gene-disease validity curation has scaled exponentially. As of July 2026, ClinGen operates over 40 fully approved Variant Curation Expert Panels (VCEPs) across 14 clinical domains, systematically separating the genomic signal from the noise.","The impact of this continuous curation is staggering when looking at the numbers. Consider Dilated Cardiomyopathy (DCM). In an updated 2026 assessment by the ClinGen DCM Expert Panel, out of 68 evaluated genes, 35 were classified into high-evidence categories (Definitive, Strong, or Moderate), a massive increase from just 19 high-evidence genes five years prior. Conversely, dozens of previously suspected genes were downgraded to Limited or Disputed as more rigorous standards were applied (Jordan et al., 2026).","This data highlights the volatility of genomic literature and underscores why clinical labs can no longer rely on static gene lists from 2020."]},{type:"prose",id:"acmg",eyebrow:"New thresholds",heading:"The new ACMG thresholds",paragraphs:["This shift toward strict gene-disease validity is becoming codified into clinical practice. The upcoming updates and current Sequence Variant Interpretation (SVI) recommendations for the ACMG/AMP guidelines are drawing a hard line: standard variant interpretation criteria cannot and should not be applied if the underlying gene-disease relationship is not established.","In practice, this means there is an explicit trend toward excluding variants that fall below a specific gene-disease validity threshold. If a gene is classified as Limited or Disputed for a phenotype, any variant found within that gene is functionally uninterpretable. Analyzing it wastes bioinformatic resources, drains variant scientist bandwidth, and unnecessarily complicates the patient's clinical report with irrelevant VUS data. As a result, commercial labs and large sequencing centers are increasingly restricting their clinical panels to only include specific genes."]},{type:"references",id:"references",eyebrow:"References",heading:"Primary sources",items:[{authors:"Jordan, E., Grover, P., Parker, P., Cowan, J., Asatryan, B., Ai, T., et al.",year:"2026",title:"An updated evidence assessment of the genetic causes of dilated cardiomyopathy",journal:"medRxiv, 2026-03",doi:"https://doi.org/10.64898/2026.03.09.26347990"},{authors:"Strande, N. T., Riggs, E. R., Buchanan, A. H., Ceyhan-Birsoy, O., DiStefano, M., Dwight, S. S., et al.",year:"2017",title:"Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource",journal:"The American Journal of Human Genetics, 100(6), 895–906",doi:"https://doi.org/10.1016/j.ajhg.2017.04.015"}]}];function D(){return e.jsx(a,{seo:{title:"Gene-Disease Validity: Reshaping Clinical Reporting | Deriva",de

1scription:"Why ClinGen's gene-disease validity framework, not variant-level scoring alone, is reshaping panel design, VUS rates, and ACMG/AMP interpretation.",path:"/blog/gene-disease-validity-clinical-reporting",image:p.url},datePublished:"2026-07-16",dateModified:"2026-07-16",hero:{eyebrow:"Blog · Variant interpretation",h1:"Beyond the Variant: Why Gene-Disease Validity is Reshaping Clinical Reporting",lede:"Before asking if a variant is pathogenic, labs now have to ask a harder question: is the gene definitively linked to the disease at all?",tldr:"Large NGS panels drove VUS rates up by analyzing genes with weak disease links. ClinGen's gene-disease validity framework, backed by 40+ VCEPs, is now the gate. The updated ACMG/AMP direction: if a gene sits at Limited or Disputed, variants in it are functionally uninterpretable and should not be reported."},meta:{readingTime:"6 min read",updatedAt:"July 2026"},miniNav:[{id:"intro",label:"Intro"},{id:"framework",label:"Framework"},{id:"data",label:"Data"},{id:"acmg",label:"ACMG"}],sections:u,faq:[{q:"What is gene-disease validity?",a:"It is the strength of evidence that variation in a specific gene causes a specific disease, classified by ClinGen from Definitive down to Disputed or Refuted."},{q:"Why does gene-disease validity matter before variant classification?",a:"If the gene-disease relationship is limited or disputed, even a damaging variant cannot support a confident clinical conclusion, so validity should be checked first."},{q:"How does ClinGen classify gene-disease validity?",a:"Expert panels score genetic and experimental evidence, producing categories such as Definitive, Strong, Moderate, Limited, Disputed, and Refuted."}],scientistCta:{eyebrow:"Start now",heading:"Rebuilding a panel around gene-disease validity?",body:"Share the gene list you're auditing and we'll show how Deriva flags Limited and Disputed associations against current ClinGen curations."},relatedReads:[{eyebrow:"Deep dive",title:"ACMG/AMP Variant Classification",description:"The 28 ACMG/AMP criteria grouped by evidence type, with the latest ClinGen SVI recalibrations.",href:"/learn/acmg-amp-variant-classification",cta:"Read the deep dive"},{eyebrow:"Guide",title:"Understanding ClinGen VCEPs",description:"How Variant Curation Expert Panels tailor ACMG/AMP to specific genes and reach ClinVar 3-star status.",href:"/resources/clingen-vcep-guide",cta:"Read the guide"},{eyebrow:"Blog",title:"Why VUS Reclassification is the Next Frontier",description:"How gene-disease validity feeds directly into the VUS reclassification backlog most labs are sitting on.",href:"/blog/vus-reclassification-next-frontier",cta:"Read the post"},{eyebrow:"Deep dive",title:"ASO Therapies Overview",description:"How ASO therapies work, the four mechanisms (splice correction, exon skipping, knockdown, WT upregulation), and how N1C guidelines assess variant eligibility.",href:"/learn/aso-therapies-overview",cta:"Read the deep dive"}],breadcrumb:[{name:"Home",item:"/"},{name:"Blog",item:"/blog"},{name:"Beyond the Variant: Gene-Disease Validity",item:"/blog/gene-disease-validity-clinical-reporting"}]})}export{D as default};